This company has shut down. Pardes Biosciences is no longer operating — its last tracked round was a Post-IPO Equity in 2021.
Explore the Startup GraveyardPardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus.
Pardes Biosciences has raised $75.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2021.
Pardes Biosciences's investors include RA Capital Management, Y Combinator, Foresite Capital, Gilead Sciences, Frazier Healthcare Partners.
Pardes Biosciences is headquartered in Carlsbad, United States.
Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus.
Pardes Biosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pardes Biosciences — Funding & Investors." VCBacked, December 27, 2021, https://www.vcbacked.co/company/pardes-biosciences. Accessed July 20, 2026.
VCBacked. (2021). Pardes Biosciences — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/pardes-biosciences
{{cite web |title=Pardes Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/pardes-biosciences |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated